Review



cd3 cd56 subset  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd3 cd56 subset
    The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated <t>CD3</t> + <t>CD56</t> + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.
    Cd3 Cd56 Subset, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 42 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+cd56+subset/PSA-NCAM+Antibody%2C+anti-human%2Fmouse%2Frat/pmc03827292-96-14-27
    Average 96 stars, based on 42 article reviews
    cd3 cd56 subset - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells"

    Article Title: Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0078980

    The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated CD3 + CD56 + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.
    Figure Legend Snippet: The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated CD3 + CD56 + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.

    Techniques Used: Incubation, Co-Culture Assay, Isolation

    The studied subpopulations included CD3 + CD56 + (A), Th17 (RORC + IL-17 + , B) and Treg (CD4 + CD25 + Foxp3 + , C) subsets. The corresponding dot plot analysis demonstrated the gating of each subset. The CIK cells were either exposed to sunitinib directly, primed with mDCs or primed with sunitinib-pretreated DCs.
    Figure Legend Snippet: The studied subpopulations included CD3 + CD56 + (A), Th17 (RORC + IL-17 + , B) and Treg (CD4 + CD25 + Foxp3 + , C) subsets. The corresponding dot plot analysis demonstrated the gating of each subset. The CIK cells were either exposed to sunitinib directly, primed with mDCs or primed with sunitinib-pretreated DCs.

    Techniques Used:

    The CD3 + CD56 + subset that had been directly exposed to sunitinib or co-cultured with sunitinib-pretreated mDCs were analyzed for the expression of IFN-γ, T-bet, IL-4, GATA-3, RORC, STAT3, and IDO.
    Figure Legend Snippet: The CD3 + CD56 + subset that had been directly exposed to sunitinib or co-cultured with sunitinib-pretreated mDCs were analyzed for the expression of IFN-γ, T-bet, IL-4, GATA-3, RORC, STAT3, and IDO.

    Techniques Used: Cell Culture, Expressing

    The CD3 + CD56 + cells from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. These conditions included the untreated CD3 + CD56 + cells, αIFN-γ treatment to CD3 + CD56 + cells, CD3 + CD56 + cells primed with mDC, αIFN-γ treatment to CD3 + CD56 + cells primed with mDC, CD3 + CD56 + cells primed with sunitinib-pretreated mDC, and αIFN-γ treatment to CD3 + CD56 + cells primed with sunitinib-pretreated mDC. * designates conditions that provided statistically difference after αIFN-γ treatment at the same E:T ratio with p<0.05.
    Figure Legend Snippet: The CD3 + CD56 + cells from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. These conditions included the untreated CD3 + CD56 + cells, αIFN-γ treatment to CD3 + CD56 + cells, CD3 + CD56 + cells primed with mDC, αIFN-γ treatment to CD3 + CD56 + cells primed with mDC, CD3 + CD56 + cells primed with sunitinib-pretreated mDC, and αIFN-γ treatment to CD3 + CD56 + cells primed with sunitinib-pretreated mDC. * designates conditions that provided statistically difference after αIFN-γ treatment at the same E:T ratio with p<0.05.

    Techniques Used: Incubation

    Related Articles

    Purification:

    Article Title: Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells
    Article Snippet: To generate macrophages, the adherent cells were maintained in 2 mL RPMI 1640, 10% FBS, 400 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF, Amoytop Biotech) for 7 d. .. An aliquot of CIK cells (1.0×10 8 cells) on day 14 was purified for CD3 + CD56 + subset using CD3 Microbeads kit and CD56 Microbeads kit (Miltenyi Biotec, Germany) according to the manufacturer instruction. ..



    Similar Products

    cd3 cd56 subset  (Miltenyi Biotec)
    96
    Miltenyi Biotec cd3 cd56 subset
    The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated <t>CD3</t> + <t>CD56</t> + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.
    Cd3 Cd56 Subset, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+cd56+subset/PSA-NCAM+Antibody%2C+anti-human%2Fmouse%2Frat/pmc03827292-96-14-27
    Average 96 stars, based on 1 article reviews
    cd3 cd56 subset - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    cd3+, cd3+cd4+, cd3+cd8+, cd19+, and cd56+cd3– lymphocyte subsets  (Becton Dickinson)
    90
    Becton Dickinson cd3+, cd3+cd4+, cd3+cd8+, cd19+, and cd56+cd3– lymphocyte subsets
    The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated <t>CD3</t> + <t>CD56</t> + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.
    Cd3+, Cd3+Cd4+, Cd3+Cd8+, Cd19+, And Cd56+Cd3– Lymphocyte Subsets, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd3+cd56+subset/anti+cd19/pm17804562-32-25-38
    Average 90 stars, based on 1 article reviews
    cd3+, cd3+cd4+, cd3+cd8+, cd19+, and cd56+cd3– lymphocyte subsets - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated CD3 + CD56 + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.

    Journal: PLoS ONE

    Article Title: Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells

    doi: 10.1371/journal.pone.0078980

    Figure Lengend Snippet: The CIK cells (A) at 1.0×10 5 cells/well from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. The CIK cell preparations comprised untreated condition, direct sunitinib treatment, macrophage co-culture, sunitinib-treated macrophage co-culture, iDC co-culture, and sunitinib-treated iDC co-culture, mDC co-culture, and sunitinib-treated mDC co-culture. The isolated CD3 + CD56 + cells (B) were studied in similar fashion. These included untreated CD3 + CD56 + cells, direct sunitinib treatment, mDC co-culture, and sunitinib-treated mDC co-culture. * and ** designate data with significant different from those of the untreated CIK cells at the same effector to target (E:T) ratio with p<0.05 and <0.01 respectively.

    Article Snippet: An aliquot of CIK cells (1.0×10 8 cells) on day 14 was purified for CD3 + CD56 + subset using CD3 Microbeads kit and CD56 Microbeads kit (Miltenyi Biotec, Germany) according to the manufacturer instruction.

    Techniques: Incubation, Co-Culture Assay, Isolation

    The studied subpopulations included CD3 + CD56 + (A), Th17 (RORC + IL-17 + , B) and Treg (CD4 + CD25 + Foxp3 + , C) subsets. The corresponding dot plot analysis demonstrated the gating of each subset. The CIK cells were either exposed to sunitinib directly, primed with mDCs or primed with sunitinib-pretreated DCs.

    Journal: PLoS ONE

    Article Title: Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells

    doi: 10.1371/journal.pone.0078980

    Figure Lengend Snippet: The studied subpopulations included CD3 + CD56 + (A), Th17 (RORC + IL-17 + , B) and Treg (CD4 + CD25 + Foxp3 + , C) subsets. The corresponding dot plot analysis demonstrated the gating of each subset. The CIK cells were either exposed to sunitinib directly, primed with mDCs or primed with sunitinib-pretreated DCs.

    Article Snippet: An aliquot of CIK cells (1.0×10 8 cells) on day 14 was purified for CD3 + CD56 + subset using CD3 Microbeads kit and CD56 Microbeads kit (Miltenyi Biotec, Germany) according to the manufacturer instruction.

    Techniques:

    The CD3 + CD56 + subset that had been directly exposed to sunitinib or co-cultured with sunitinib-pretreated mDCs were analyzed for the expression of IFN-γ, T-bet, IL-4, GATA-3, RORC, STAT3, and IDO.

    Journal: PLoS ONE

    Article Title: Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells

    doi: 10.1371/journal.pone.0078980

    Figure Lengend Snippet: The CD3 + CD56 + subset that had been directly exposed to sunitinib or co-cultured with sunitinib-pretreated mDCs were analyzed for the expression of IFN-γ, T-bet, IL-4, GATA-3, RORC, STAT3, and IDO.

    Article Snippet: An aliquot of CIK cells (1.0×10 8 cells) on day 14 was purified for CD3 + CD56 + subset using CD3 Microbeads kit and CD56 Microbeads kit (Miltenyi Biotec, Germany) according to the manufacturer instruction.

    Techniques: Cell Culture, Expressing

    The CD3 + CD56 + cells from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. These conditions included the untreated CD3 + CD56 + cells, αIFN-γ treatment to CD3 + CD56 + cells, CD3 + CD56 + cells primed with mDC, αIFN-γ treatment to CD3 + CD56 + cells primed with mDC, CD3 + CD56 + cells primed with sunitinib-pretreated mDC, and αIFN-γ treatment to CD3 + CD56 + cells primed with sunitinib-pretreated mDC. * designates conditions that provided statistically difference after αIFN-γ treatment at the same E:T ratio with p<0.05.

    Journal: PLoS ONE

    Article Title: Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3 + CD56 + Subset through the Co-Culturing Dendritic Cells

    doi: 10.1371/journal.pone.0078980

    Figure Lengend Snippet: The CD3 + CD56 + cells from each condition were incubated with the attached HubCCA1 cells (5,000 cells/well) for 4 h before the PI assay. These conditions included the untreated CD3 + CD56 + cells, αIFN-γ treatment to CD3 + CD56 + cells, CD3 + CD56 + cells primed with mDC, αIFN-γ treatment to CD3 + CD56 + cells primed with mDC, CD3 + CD56 + cells primed with sunitinib-pretreated mDC, and αIFN-γ treatment to CD3 + CD56 + cells primed with sunitinib-pretreated mDC. * designates conditions that provided statistically difference after αIFN-γ treatment at the same E:T ratio with p<0.05.

    Article Snippet: An aliquot of CIK cells (1.0×10 8 cells) on day 14 was purified for CD3 + CD56 + subset using CD3 Microbeads kit and CD56 Microbeads kit (Miltenyi Biotec, Germany) according to the manufacturer instruction.

    Techniques: Incubation